

# Improving preservation practice

Allison Hubel, Ph.D  
University of Minnesota




# Cryopreservation and transport

Sites:

- Donation
- Cell processing
- Clinical use

Cells must be transported between sites and retain viability

Cell processing facility



Sites of use:


- Hospital
- Doctors office
- Battlefield

Laboratory for  
Biomechanics and  
Biothermodynamics



# Cryopreservation and quality control


Harvest




Processing



Quality Control




Administration



- Expansion
- Selection of subpopulations
- Genetic modification
- Biological modification




# Manufacturing paradigm



With  
cryopreservation



Without  
cryopreservation



 Product A

 Product B



Laboratory for  
Biomechanics and  
Biothermodynamics



# Other benefits of cryopreservation

- Pooling of cells to reach therapeutic dose
- Increasing genetic diversity of cells



Liquid storage/  
prefreeze processing

Introduction of solution

Cooling protocol

Storage conditions

Warming protocol

Post thaw assessment

# Components of a Cryopreservation Protocol



# Importance of preservation practice

- Each element of protocol is important
- Subtle mistakes have profound results
- Improving preservation practice requires
  - Good practices
  - Ongoing research




# Prefreeze processing

*What happens to a cell before freezing influences post thaw recovery*

**Improving your practice:** Monitor cell health (not viability) before freezing

- Apoptosis
- Shifts in metabolism



Van den Einden, Cytometry, 1997

Slide 8


Laboratory for  
Biomechanics and  
Biothermodynamics





# Introducing solutions

- Preservation requires the use of specialized solutions
- Solutions are not physiological
- Introduction and removal of the solutions can result in cell death
  - Osmotic stress
  - Biochemical toxicity



Slide 9



# Improving preservation practice

- Select an acceptable level of cell loss
- Measure losses from introduction and removal only (no freezing)
- Modify introduction protocol to reduce losses
  - Gradual/stepwise introduction
  - Introduction at reduced temperatures



# Improving practice

- Cell density during freezing influences post thaw recovery
- Freezing at cell densities  $> 20\%$  cytocrit, results in reduced post thaw recovery
- **Calculate** the concentration at which you freeze
- **Modify** cell concentration, if needed



# Cell Density, cont.

Relationship between cell density and cytocrit:

$$C = \frac{V_{totalcell}}{V_{total}}$$

Sample calculation: Estimate the maximum cell concentration for a cell with diameter of 20  $\mu$ m

$$V_{cell} = \frac{4}{3} \pi r^3 = \frac{4}{3} \pi (10 \times 10^{-6} \text{ m})^3 = 4.2 \times 10^{-15} \text{ m}^3 = 4.2 \times 10^{-9} \text{ ml}$$

$$0.2 = C V_{cell} \quad C = 48 \times 10^6 \text{ cells / ml}$$



# Controlled rate freezing, cont.

*In search of the perfect curve.....*

- Common deviations:
  - Delayed latent heat of fusion
  - Failure during controlled rate freezing
- Problems during CRF can reduce viability

QuickTime™ and a  
decompressor  
are needed to see this picture.



McCullough, Transfusion, to be submitted



# Cooling protocol

Temperature history  
during controlled rate  
freezing varies with:

- Sample volume
- Sample container
- Location in freezer



# Cooling protocol cont.

*Fundamental problem: actual temperature history of every sample is not known.*

*Actual freezing curve is not known*

*“Optimal curve” cannot be determined.*



# Improving preservation practice: new technology

- Temperature as a function of time must be monitored:
  - Freezing
  - Storage
    - ‘rewarming’
- In development: a temperature sensor for each sample being frozen





# Storage/repositories

Samples that are frozen are stored in a repository

Key questions:

- What is being stored
  - Volume
  - Container (vial, straw, bag)
- Why is it being stored
- How many samples are being stored

*Design of repository should reflect those issues*



# Repositories, cont.

- LN<sub>2</sub> usage is strongly influenced by
  - Frequency of access
  - Line losses (delivery system)
  - Physical layout
  - Valve configuration
  - Number of freezers/storage units



# Improving your practice

- Develop a central repository for multiple users
- Train personnel on accessing a repository
  - Minimizing thermal excursions for repository and sample
- Times for accessing repository are limited



# DMSO Disconnect




*Medicate  
patient to  
attenuate  
adverse  
effects*

*Removing DMSO  
takes too much  
time and there are  
too many cells lost*



***This is an  
awful  
experience***



# DMSO: adverse effects

- DMSO is not approved for human infusion
- Adverse effects are well documented
  - Common effects (nausea, dyspnea)
  - Less common (cardiac, renal)
  - Recent studies document neurological effects
- **Needed technology investment:** removing DMSO with minimal cell losses




# Improving preservation practice: post thaw processing

Current methods:  
centrifugation


## Problems:

- Labor intensive
- Operator dependent
- Cell losses are significant (25-30%)



# Microfluidic technology

- Low power requirements
- Control of cell motion
- Reduced labor
- Reduced stresses on cells



Mata, Lab on a Chip, 2008



# Microfluidic device, cont

<b><i>CVF</i></b>	<b><math>(1/Pe)*(L/d)</math></b>		<b><math>Cc^{*a}</math></b>
<b>%</b>		<b>ml/min</b>	<b>exp</b>
0	1.2E-01	0.85	0.03
0	7.3E-02	1.41	0.05
2	7.3E-02	1.41	0.09

- *>95% DMSO removed*
- *Cell recovery ~90% □*
- *1.5 ml/min processed*






# Post thaw assessment

*It is easy to perform post thaw assessment badly*

## ***Kansas Stem Cell Program Sued***

October 2006

A group of patients has sued a Kansas City stem cell transplant program alleging that it used shortcut methods to prepare the cells, resulting in the deaths of one-fourth of 40 patients treated between 1998 and 1999. Those patients died within 100 days of the treatments from complications including hemorrhages, infections and the return of their cancer. In two years, half of the patients died -- a much higher death rate than other centers.



# Post thaw assessment

*Assessing the viability of a frozen and thawed cell is not the same as assessing the viability of a cell*



# Post thaw assessment

Freezing and thawing produces:

- Changes in membrane integrity
- Metabolic function
- Tendency toward apoptosis

Implying that:

- Membrane integrity tests  $\neq$  viability
- Viability may change with time post thaw



# Measurement Bias

## Prefreeze Assay

Total number of cells = 100

Number of target cells = 7



Frequency of target cells =  $7/100 = 7\%$

## Post thaw Assay

Total number of cells = 71

Number of target cells = 5

Frequency of target cells =  $5/71 = 7\%$



# Measurement Bias, cont.

## Current method of accounting

Recovery of target cell = frequency of target cell  
post thaw / frequency of target cell prefreeze =  
 $0.07/0.07=100\%!!!$

⇒ Measurement Bias

You have not accounted for the cells that were  
lost

Recovery of target cell = total number of target  
cells post thaw / total number of target cells  
prefreeze



# Summary

## Operator-based improvements:

- Testing each element of protocol
- Developing good practices for repositories
- Validating post thaw assessment methods


## New developments:

- Technologies that reduce labor and operator dependence
- Appropriate monitoring technology
- Nontoxic alternatives to DMSO

*The ability to preserve cells is integral to cell therapy. Advances in the field are necessary to improve outcome.*



# Professional short course



## Topics covered:

- Liquid storage of cells and tissues.
- Fundamentals of cryopreservation
- Protocol development
- Quality systems
- Clinical cell cryopreservation
- Repository design
- Gamete preservation
- Tissue preservation
- Regulatory issues for cell/tissues

## Lecturer

- Allison Hubel, University of Minnesota
- Charles Lee, University of North Carolina, Charlotte
- Ian Pope, CoreCryolab
- Ken Roberts, University of Minnesota
- Marilyn Waxberg, RCRI
- Alptekin Aksan, University of Minnesota
- David McKenna, University of Minnesota
- Diane Kadidlo, University of Minnesota



# Acknowledgements

- People
  - Ellen Longmire
  - David McKenna
  - Katie Fleming
  - Clara Mata
- Funding
  - 3M Foundation Fellowship
  - University of Minnesota Grant-in-aid Program
  - National Blood Foundation
  - National Institutes of Health
  - Medical Device Center

